Caesarean section for placenta praevia complicated by postpartum haemorrhage managed successfully with recombinant activated human coagulation Factor VIIa

Gidiri, Muchabayiwa Francis; Noble, William D.; Rafique, Zunaira; Patil, Kewal; Lindow, Stephen W.

doi:10.1080/01443610400019120

Cited by 10 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of rFVIIa for hemostasis has been reported in an increasing number of cases, but its use in the field of obstetrics is still limited. Using ‘pregnancy and recombinant activated factor VII’ as key words to search PubMed, we found 26 case reports or case series (Table 3) 16–41 and five reviews 13,42–45 regarding the use of rFVIIa. The case series included 15 reports on the hemostatic use of rFVIIa for treatment of DIC due to obstetric hemorrhage.…”

Section: Discussionmentioning

confidence: 99%

Successful management by recombinant activated factor VII in a case of disseminated intravascular coagulopathy caused by obstetric hemorrhage

Nohira¹,

Osakabe²,

Suda

et al. 2008

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Postpartum hemorrhage (PPH) is a life-threatening emergency in obstetrics. Although recombinant activated factor VII (rFVIIa) has become used for the treatment of some cases of massive hemorrhage, its applications in the field of obstetrics are still limited. We describe a case of successful treatment with rFVIIa for PPH due to placenta accreta. The patient was a 33-year-old woman with placental previa. Cesarean section (CS) was performed at gestational week 35. During CS, there was massive hemorrhage due to placenta accreta. After CS, disseminated intravascular coagulopathy and hypovolemic shock were diagnosed. The PPH was not controlled by transfusion therapy. On the fourth day after CS, rFVIIa (90 microg/kg x 2) was given because of the persistent PPH. Bleeding decreased and no further transfusion was required from 2 days after administration. rFVIIa was useful in the treatment of this case of obstetric hemorrhage.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful management by recombinant activated factor VII in a case of disseminated intravascular coagulopathy caused by obstetric hemorrhage

Nohira¹,

Osakabe²,

Suda

et al. 2008

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…A Medline search using keywords related to 'recombinant activated factor VII', 'obstetrics', 'gynecology' or 'pregnancy' for the period from January 2000 to June 2006 resulted in 24 publications in English describing the use of rFVIIa in 56 patients. The majority of the publications (18, 75%) describe the use of rFVIIa in patients without hematological disease (TABLE 2) [15,[51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67]. Of the 56 patients, rFVIIa was used most often to treat PPH (47 patients, 84%).…”

Section: Overview Of the Current Evidence On The Use Of Rfviia In Obsmentioning

confidence: 98%

Overview on the use of recombinant factor VIIa in obstetrics and gynecology

Scarpelini

Nascimento

Tien

et al. 2007

Expert Review of Obstetrics & Gynecology

View full text Add to dashboard Cite

Bleeding remains a major cause of morbidity and mortality in obstetrics and gynecology. A unique drug, recombinant factor VIIa (rFVIIa), has been introduced recently for the management of surgical bleeding. This novel application of a drug that was restricted to hemophilia treatment for over 10 years has generated intense interest among surgeons. This article reviews the importance of bleeding in obstetrics and gynecology, the characteristics of this drug, including side effects, and all the evidence available on rFVIIa use in obstetrics and gynecology. Expert commentary on rFVIIa is presented with recommendations on its clinical application. rFVIIa is a fascinating adjunct therapy that is undergoing rapid and extensive investigation. rFVIIa has the potential to change the current standards of hemorrhage care in surgical patients, including obstetrics and gynecology patients.

show abstract

“…Unpublished works were identified by searching the abstract books of the most important conferences on obstetric and hematological diseases. A total of 31 articles were retrieved from the literature search 22–52 …”

Section: Literature Searchmentioning

confidence: 99%

“…Table 1 analyzes in detail the studies. Our analysis of the published data identified 31 articles/abstracts including 97 patients with PPH receiving rFVIIa 22–52 . In those reports cesarean section is associated with an increased risk of onset of PPH as, among the 85 deliveries reported, 32 (37.6%) were by vaginal route and 53 (62.4%) by cesarean section.…”

Section: The Role Of Rfviia In Pphmentioning

confidence: 99%

The use of recombinant activated factor VII in life‐threatening postpartum hemorrhage

Franchini

2007

Transfus Alt Transfus Med

View full text Add to dashboard Cite

Bleeding is still a major cause of morbidity and mortality in obstetrics. As recent reports have documented the successful treatment of some cases of postpartum hemorrhage (PPH) refractory to standard treatment with recombinant activated factor VII (rFVIIa), we have performed a systematic review of the existing literature on this topic. Although supported by few and uncontrolled studies, on the whole the published data suggest a potential role of rFVIIa in the management of severe PPH. However, further evidences are needed in order to better assess the optimal dose, the effectiveness and the safety of rFVIIa in such critical bleeding condition.Publication data

show abstract

Caesarean section for placenta praevia complicated by postpartum haemorrhage managed successfully with recombinant activated human coagulation Factor VIIa

Cited by 10 publications

References 5 publications

Successful management by recombinant activated factor VII in a case of disseminated intravascular coagulopathy caused by obstetric hemorrhage

Successful management by recombinant activated factor VII in a case of disseminated intravascular coagulopathy caused by obstetric hemorrhage

Overview on the use of recombinant factor VIIa in obstetrics and gynecology

The use of recombinant activated factor VII in life‐threatening postpartum hemorrhage

Contact Info

Product

Resources

About